参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Hepatobiliary Cancers Version 1.2019-December 17, 2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Fong ZV, Tanabe KK.The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review.Cancer 2014, 120: 2824-2838.
4.Petrick JL, Kelly SP, Altekruse SF, et al.Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.J Clin Oncol 2016, 34: 1787-1794.
5.de Martel C, Maucort-Boulch D, Plummer M, et al.World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.Hepatology 2015, 62: 1190-1200.
6.Ogata F, Kobayashi M, Akuta N, et al.Outcome of alloral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease.Oncology 2017.
7.Kim WR, Loomba R, Berg T, et al.Impact of longterm tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.Cancer 2015, 121: 3631-3638.
8.Feng Q, Chi Y, Liu Y, et al.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a metaanalysis of 23 studies.J Cancer Res Clin Oncol 2015, 141: 1-9.
9.Brown KT, Do RK, Gonen M, et al.Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone.J ClinOncol 2016.
10.Zhu AX, Rosmorduc O, Evans TR, et al.SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.J Clin Oncol 2015, 33: 559-566.
11.Malaguarnera G, Paladina I, Giordano M, et al.Serum markers of intrahepatic cholangiocarcinoma.Dis Markers 2013, 34: 219-228.(https://www.daowen.com)
12.Hong TS, Wo JY, Yeap BY, et al.Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol 2016, 34: 460-468.
13.Sia D, Tovar V, Moeini A, et al.Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.Oncogene 2013, 32: 4861-4870.
14.Wang P, Dong Q, Zhang C, et al.Mutations in isocitrate dehydrogenase1and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.Oncogene 2013, 32: 3091-3100.
15.Zhu AX, Borger DR, Kim Y, et al.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Ann Surg Oncol 2014, 21: 3827-3834.
16.Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al.SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma.J Clin Oncol 2015, 33: 2617-2622.
17.Ghafoori AP, Nelson JW, Willett CG, et al.Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.Int J Radiat Oncol Biol Phys 2010.
18.Moureau-Zabotto L, Turrini O, Resbeut M, et al.Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma.BMC Cancer 2013, 13: 568.
19.Bruix J, Takayama T, Mazzaferro V, et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol 2015, 16: 1344-1354.
20.Bruix J, Qin S, Merle P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE): a randomised, doubleblind, placebo-controlled, phase 3 trial.Lancet 2017, 389: 56-66.
21.Erhardt A, Kolligs F, Dollinger M, et al.TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.Cancer Chemother Pharmacol 2014, 74: 947-954.
22.Zhao Y, Wang WJ, Guan S, et al.Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.Ann Oncol 2013, 24: 1786-1792.